RealTalk MS
Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In today's episode, you'll meet two participants from the TEAMS Study, a research study at the University of Illinois Chicago's UI Health, in conjunction with the University of Alabama Birmingham School of Public Health. TEAAMS is an acronym for Targeted Exercise for African-Americans with Multiple Sclerosis. And the study's research team analyzed the effects of a remotely delivered, racially tailored exercise training program among African Americans with MS...
info_outlineRealTalk MS
Being a caregiver for a loved one with MS isn't an easy job. And, while it may consume hours of your time, often, it's not your only job. Many caregivers are the only family members bringing in an income. So, in addition to their caregiving responsibilities, they may also be facing the responsibilities that go along with holding down a full-time job. This week, Diana Grazio joins me to discuss how she balances her roles and responsibilities as her partner's caregiver while holding down a full-time job. You have online opportunities tomorrow! Participate in the National MS...
info_outlineRealTalk MS
As researchers continue to learn about MS, it becomes clear that you can change the trajectory of your MS journey and improve your quality of life by making smart lifestyle choices. Quitting smoking and watching your alcohol and caffeine consumption are smart choices for everyone, and they can pay especially big dividends if you're living with MS. This week, Dr. Barbara Giesser discusses how smoking, consuming alcohol, and consuming caffeine can impact your MS. We're also sharing the details about the Black MS Experience Summit taking place on November 12th, and the Hispanic LatinX MS...
info_outlineRealTalk MS
When you're living with a chronic condition like MS, you want to be sure you're doing everything you can to preserve and promote good health. And, right now, you may be feeling confused about whether you should be getting vaccinated, and which vaccines are safe. It's understandable. Unfortunately, there's a lot of confusing information about vaccines and vaccinations floating around out there. This week, Dr. Lisa Doggett helps us get past all the unnecessary noise and hysteria and reviews the science-based vaccine recommendations for people living with MS. We're also talking about...
info_outlineRealTalk MS
Some disease-modifying therapies can change the trajectory of your MS journey. But gaining access to those medications isn't always as easy or straightforward as it should be. In the United States, insurance companies are most often the gatekeepers to prescription medications. This week, Cassandra Ashby shares a story that many of you may already be too familiar with, as she takes us through her family's long, hard, and confusing struggle to get the DMT that her newly-diagnosed daughter's neurologist prescribed. I We're also talking about the game-changing results of a study that...
info_outlineRealTalk MS
Just about a month ago, 9,600 researchers, clinicians, and representatives from patient advocacy organizations gathered in Barcelona for the European Committee on Treatment and Research in MS annual scientific congress, better known as ECTRIMS, the largest MS research conference in the world. Now that he's had an opportunity to review his notes and digest all of the science presented at ECTRIMS 2025, Dr. Bruce Bebo, the National MS Society's Executive Vice-President of Research, returns to the podcast to take us on a deep dive covering some of the most important research presented this year....
info_outlineRealTalk MS
Jan Janisch-Hanzlik lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. Jan is the first person in the world to receive this one-and-done treatment, and this week, she's joining me to share her experience participating in the clinical trial. But you'll be especially interested in hearing how CAR-T cell therapy has impacted Jan's MS. Open enrollment for people with Medicare and for those who get their health insurance through the ACA healthcare.gov Marketplace begins this week, and we're talking about some of the...
info_outlineRealTalk MS
Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In today's episode, we're exploring the risks and rewards of participating in a clinical trial with Dr. Kathy Zackowski and Mimi Brown. Dr. Zackowski is the Associate Vice President of Research at the National MS Society, and she's going to offer an overview of the risks and benefits that you'll want to weigh in considering participating in a clinical trial. Mimi Brown lives with primary progressive MS, and Mimi is...
info_outlineRealTalk MS
From the earliest days of the COVID-19 pandemic, people living with MS have been justifiably concerned about how a COVID-19 infection might impact their MS. As the new "Stratus" strain of COVID-19 is currently surging in the United States, research is providing answers we didn't have five years ago. Dr. Robert Fox, the Managing Director of the NARCOMS Patient Registry, joins me to discuss how COVID-19 infections and other infections impact people with MS. As ECTRIMS, the world's largest MS research conference, approached, many attendees anticipated the FDA's decision on whether to approve...
info_outlineRealTalk MS
Last week, over 9600 MS researchers and clinicians gathered in Barcelona for the European Committee for Treatment and Research in Multiple Sclerosis annual scientific congress -- ECTRIMS 2025. Minutes after the conference adjourned, in what has become an annual tradition, Dr. Bruce Bebo, the Executive Vice President of Research at the National MS Society, joined me to share his initial thoughts on the science presented at the meeting. Then, Kristine Werner Ozug, a member of the RealTalk MS team who lives with MS, joined me to share her perspective on three non-stop days of...
info_outlineYou're living with MS, and maybe you're thinking about participating in an MS clinical trial. But how do they work? Are they safe? What's the difference between Phase 1, 2, and 3 trials? What are the real patient risks and benefits of participating in a clinical trial?
In this special episode of RealTalk MS, we're getting answers to those questions and so much more from my guest, Dr. Aaron Boster.

Dr. Boster is the founder of the Boster Center for Multiple Sclerosis in Columbus, Ohio, where he brings over 20 years of experience as an MS clinician. Dr. Boster has also participated in more than 65 clinical trials.
This special episode of RealTalk MS has been made possible through a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/ct1
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Email: jon@realtalkms.com
Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!